Encompass RNA test to help stratify asymptomatic pregnant women into high or low risk for preeclampsia, and support early preventive care interventions
Mirvie, Inc., in partnership with Advantia Health, has launched a first-of-its-kind pilot program in the U.S. to improve pregnancy outcomes. The program uses the clinically validated Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia, enabling clinicians to initiate preventive care for the appropriate patients.
Health Technology Insights: DarioHealth Announces CFO Transition
The potential to impact pregnancy health is huge. We have been operating without objective data. This test allows us to identify and focus on the few patients at truly high risk with a preventive care plan.
Preeclampsia, a dangerous pregnancy complication, has nearly doubled in recent years and now affects 1 in 12 pregnancies, costing the U.S. healthcare system billions each year. Current risk assessment methods have proved ineffective, leading to high rates of preterm deliveries, neonatal ICU admissions, and preventable deaths.
“The potential to impact pregnancy health is huge. We have been operating without objective data. This test allows us to identify and focus on the few patients at truly high risk with a preventive care plan,” said Dr. Jo’Ann Jackson, Regional Chief Medical Officer of the Mid-Atlantic, Advantia Health.
“Until now, we have lacked an effective and objective test to assess risk for preeclampsia in patients with no known risk factors. The Encompass test helps resolve this ambiguity of risk, ensuring the right pregnancies get the right preventive care. We are bringing a level of personalized care, based on molecular signatures, that has been long available in oncology, but for the first time can now be brought to pregnancy care,” said Dr. Thomas McElrath, Vice President of Clinical Development at Mirvie, and practicing physician in Maternal Fetal Medicine at Brigham and Women’s.
Health Technology Insights: Novotech Unveils IPF Trial Opportunities with New Insights
“We know innovations in maternal health are needed,” said Dr. Michael Udwin, Medical Director, CareFirst BlueCross BlueShield (CareFirst). “We are excited about the potential for improved outcomes for both mother and baby through Mirvie’s collaboration with Advantia Health, which provides care to many CareFirst members.”
This year-long collaboration, which launches immediately, reflects Advantia Health’s commitment to improving pregnancy outcomes in the mid-Atlantic region and Mirvie’s commitment to bringing a precise standard of care to pregnancy health.
Health Technology Insights: Inocras, Center for Data-Driven Discovery Collaborate on Sinonasal Cancer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
